Skip to main content

New COVID-19 Boosters To Roll Out Mid-September

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

FRIDAY, Aug. 25, 2023 -- New COVID-19 booster shots, reworked to target variants circulating now, could be available by mid-September, providing an opportunity for people to boost waning antibodies to the virus.

The U.S. Food and Drug Administration is expected to approve them in a few weeks, CNN reported, citing unnamed senior administration officials. The U.S. Centers for Disease Control and Prevention will soon follow with a safety review and its recommendations. Its Advisory Committee on Immunization Practices is scheduled to meet Sept. 12.

Americans are expected to be able to choose between two mRNA vaccines made by Pfizer and Moderna, as well as a protein subunit vaccine from Novavax. The Novavax vaccine contains an ingredient to boost the immune system to make antibodies, CNN reported. The FDA plan is to approve the Pfizer and Moderna vaccines for people ages 12 years and older. It is expected to allow the Novavax vaccines, as well as vaccines for those age 11 years and younger, under an emergency use authorization, CNN reported.

The new vaccines will target the XBB.1.5 coronavirus subvariant and offer some protection for closely related strains. They are also effective against EG.5. There will not be free government coverage, though most insurance plans are required to pick up the full cost, without copays, under the Affordable Care Act. People with no insurance can use a government bridge program to get vaccines for free.

"That bridge program will exist through a few channels," CDC Director Mandy Cohen, M.D., M.P.H., said in an interview with CNN. "Folks can go to a federally qualified health center or they can go to their public health department. … And then the third option is, we are working with pharmacy partners such as CVS, Walgreens, Walmart, and others to have it available in the pharmacies as well."

CNN Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Further Support and Information on COVID-19

Read this next

COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes

TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...

Cannabis Use Tied to Risk of COVID-19 Hospitalizations, ICU Admissions

TUESDAY, June 25, 2024 -- Current cannabis use may be an independent risk factor for COVID-19–related complications, according to a study published online June 21...

FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine

FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.